Tauklarify is an FDA-approved PET imaging drug that lets doctors see tau tangles — a hallmark protein buildup of Alzheimer's disease — inside a living brain. The FDA cleared it on August 14, 2026, as florquinitau F 18 injection (also known as MK-6240), made by Lantheus, for adults being evaluated for Alzheimer's, according to SNMMI. For families facing younger-onset Alzheimer's, where symptoms start before age 65 and often look different from typical late-life dementia, a new tau scan raises practical questions beyond "does it exist." The sections below lay out what to ask a clinician before agreeing to the scan, what the approval does and does not cover, and what to expect logistically and financially.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Tauklarify actually show, and why does that matter for Alzheimer's?
- Is this scan appropriate for younger-onset Alzheimer's specifically?
- How accurate is the scan, and what happens if the result is unclear?
- What does the appointment involve, and is it available nearby?
- What will it cost, and is it covered by insurance?
- Frequently Asked Questions
What does Tauklarify actually show, and why does that matter for Alzheimer's?
Tauklarify is a radioactive tracer injected into a vein; once in the brain, it binds to tau neurofibrillary tangles, a twisted protein structure found inside neurons in Alzheimer's disease. A PET scanner then captures where and how much tau has accumulated, giving clinicians a picture of disease burden they cannot get from a cognitive test alone, per SNMMI. Tangles are one of two defining features of Alzheimer's, alongside sticky amyloid plaques.
Lantheus has positioned tau PET as a complement to amyloid PET rather than a replacement, so a family should ask whether their clinician is ordering tau imaging alongside an amyloid scan, or instead of one, and what each result would add to the picture, according to Healio. Tauklarify is also only the second tau tracer ever approved by the FDA, after Eli Lilly's flortaucipir (Tauvid) in 2020. A reasonable question for any clinic is which tracer it uses and why, since the two are not identical products, per AuntMinnie.
Is this scan appropriate for younger-onset Alzheimer's specifically?
Tauklarify's FDA label covers adults with cognitive impairment being evaluated for Alzheimer's disease in general. It was not validated as a tool specifically for younger-onset cases, so a family should ask the clinician to confirm that the planned use matches this general approved indication rather than an off-label application, according to Healio. It is also worth asking whether Alzheimer's, specifically, is the suspected diagnosis. The FDA has stated that Tauklarify's safety and effectiveness have not been established for evaluating other tau-related dementias, sometimes called non-Alzheimer's tauopathies.
A family should confirm the clinician is scanning for Alzheimer's tangles and not a different tau disorder before the appointment is scheduled, per Applied Radiology. Younger-onset Alzheimer's often presents atypically — with language, visual, or behavioral symptoms rather than classic memory loss — which makes the scan's interpretation more relevant to ask about, not less. Imaging research has found that younger patients tend to show more tau uptake in frontal and parietal brain regions than older patients, and that atypical presentations such as posterior cortical atrophy carry their own distinct tau patterns, according to a Frontiers in Neuroscience review. A useful question for the clinician is whether they will read the scan with the patient's specific symptom pattern in mind, rather than against a generic template built from typical late-onset cases.
How accurate is the scan, and what happens if the result is unclear?
Tauklarify's approval was based on two blinded-read studies drawing on scans from more than 500 subjects across three trials. Readers agreed with a positive tau finding 68% to 88% of the time and agreed with a negative finding 93% to 99% of the time, according to NeurologyLive.
That range means a misread is possible, and a family can reasonably ask how confident the reading radiologist is in a given result and whether a second reader will review the images. Because the scan is one piece of a larger workup, it's worth asking directly what a positive or a negative tau result would change about the diagnosis or the care plan. Lantheus has described tau PET as adding information to, rather than overriding, an amyloid PET result, so the two scans together may tell a more complete story than either alone, per Healio.
What does the appointment involve, and is it available nearby?
The scan itself is straightforward: Tauklarify is given as a single intravenous injection, followed by about a 90-minute wait before a roughly 20-minute PET scan. Families should ask the clinic how long to block off for the full visit and whether any preparation, such as fasting, is required beforehand, according to Drugs.com.
Availability is a separate question from approval. Lantheus's own announcement flagged commercial launch timing as an open item, meaning not every imaging center will offer the scan immediately after FDA clearance, per Lantheus's announcement via Barchart. A family should ask their clinician or hospital's imaging department directly whether the scan is currently offered on-site or requires a referral elsewhere.
What will it cost, and is it covered by insurance?
Coverage for tau PET is unsettled. There is no Medicare national coverage determination specific to tau PET imaging yet. CMS has removed the stricter coverage-with-evidence requirement that once applied to amyloid PET, but tau PET coverage is left to local Medicare contractors, according to the American College of Radiology.
That makes coverage decisions inconsistent from one region to another. Lantheus itself named obtaining adequate insurance coding, coverage, and payment as a risk tied to the drug's rollout, per Lantheus's announcement. Before scheduling, families should: A clear answer on coverage before the appointment avoids a bill that arrives months later with no advance warning.
- Call their insurer directly and ask whether tau PET imaging is a covered benefit under their specific plan, rather than relying on general Medicare policy.
- Ask the imaging center for the billing codes it plans to use, so the insurer can be asked about those exact codes.
- Ask the clinician's office whether it has experience getting the scan approved and paid for other patients yet, given how recent the approval is.
Frequently Asked Questions
Does Tauklarify replace the need for an amyloid PET scan?
No. Lantheus has positioned tau PET as complementary to amyloid PET, not a substitute, so many clinicians order both to build a fuller picture, according to Healio.
Is Tauklarify the only approved tau PET tracer?
No. It is the second, after Eli Lilly's Tauvid (flortaucipir) was approved in 2020, per AuntMinnie.
How long does the Tauklarify scan take?
The injection is followed by about a 90-minute wait, then a roughly 20-minute PET scan, according to Drugs.com.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
